INVOKANA Drug Patent Profile

Which patents cover Invokana, and when can generic versions of Invokana launch?

Invokana is a drug marketed by Janssen Pharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twenty patent family members in forty-five countries.

The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the canagliflozin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Invokana

A generic version of INVOKANA was approved as canagliflozin by APOTEX on April 14^th, 2026.

Summary for INVOKANA

International Patents:	220
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVOKANA

Paragraph IV (Patent) Challenges for INVOKANA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVOKANA	Tablets	canagliflozin	100 mg and 300 mg	204042	10	2017-03-29

US Patents and Regulatory Information for INVOKANA

INVOKANA is protected by three US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013	AB	RX	Yes	No					Y
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-002	Mar 29, 2013	AB	RX	Yes	Yes					Y
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013	AB	RX	Yes	No
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-002	Mar 29, 2013	AB	RX	Yes	Yes					Y
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013	AB	RX	Yes	No					Y
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013	AB	RX	Yes	No					Y

International Patents for INVOKANA

When does loss-of-exclusivity occur for INVOKANA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Hong Kong

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVOKANA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2004261663	Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
Brazil	PI0413232	novos compostos tendo atividade inibitória contra os trasnportadores dependentes de sódio
New Zealand	577545
Uruguay	33380	FORMULACIONES FARMACÉUTICAS QUE CONTIENEN DERIVADOS DE 1-(B(BETA)-D-GLUCOPIRANOSILO) Y SUS USOS
Taiwan	I385177
Brazil	112012028857	formulações farmacêuticas que compreendem derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenzeno como inibidores de sglt

Supplementary Protection Certificates for INVOKANA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1651658	C20140011 00102	Estonia		PRODUCT NAME: KANAGLIFLOSIIN;REG NO/DATE: K(2013)8171 (LOPLIK) 15.11.2013
1651658	C 2014 017	Romania		PRODUCT NAME: CANAGLIFLOZIN; NATIONAL AUTHORISATION NUMBER: EU/1/13/884; DATE OF NATIONAL AUTHORISATION: 20131115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/884; DATE OF FIRST AUTHORISATION IN EEA: 20131115
1651658	92426	Luxembourg		PRODUCT NAME: CANAGLIFLOZINE
1651658	637	Finland
1651658	C01651658/01	Switzerland		PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 62956 29.01.2014
1651658	SPC/GB14/032	United Kingdom		PRODUCT NAME: CANAGLIFLOZIN; REGISTERED: UK EU/1/13/884/001 20131119; UK EU/1/13/884/002 20131119; UK EU/1/13/884/003 20131119; UK EU/1/13/884/004 20131119; UK EU/1/13/884/005 20131119; UK EU/1/13/884/006 20131119; UK EU/1/13/884/007 20131119; UK EU/1/13/884/008 20131119

Investment Scenario, Market Dynamics, and Financial Trajectory for INVOKANA

Last updated: February 3, 2026

Executive Summary

This comprehensive analysis evaluates INVOKANA (canagliflozin), a leading SGLT2 inhibitor approved for type 2 diabetes mellitus (T2DM) treatment by Janssen Pharmaceuticals (a Johnson & Johnson subsidiary). It assesses investment opportunities, market landscape, competitive positioning, and financial projections based on regulatory, clinical, and commercial factors.

Key findings:

• Market penetration driven by expanding indications and cardiovascular/renal benefits.
• Competitive landscape dominated by SGLT2 inhibitors: Invokana, Jardiance, Farxiga.
• Revenue growth forecasted at a CAGR of approximately 8% over 5 years, driven by expanding global adoption.
• Patent exclusivity ending by 2025–2027, imposing potential challenges from biosimilars.
• Strategic opportunities include combination therapies and label expansions.

---

Market Overview and Dynamics

Global Market Size and Growth

Parameter	2022 (USD billion)	Projected 2027 (USD billion)	CAGR (2022–2027)
T2DM Pharmacological Market	$58.2	$82.9	8.3%
SGLT2 Inhibitors Market	$6.3	$12.1	15.1%

Source: [1], [2]

The overall diabetes therapeutics market demonstrates steady growth, with SGLT2 inhibitors capturing increasing market share due to proven cardiovascular and renal benefits.

Regulatory and Label Expansion Trends

• Initially approved in 2013 for T2DM.
• Broadened indications to include heart failure (March 2022 by the FDA).
• Recent label updates for chronic kidney disease (CKD) management.
• Globally expanding approvals especially in Europe, Asia-Pacific.

Market Drivers

• Rising prevalence of T2DM (approx. 537 million globally, projected to reach 643 million by 2030 [3]).
• Increasing recognition of cardiorenal benefits reducing hospitalizations.
• Growing adoption in primary care settings.
• Favorable reimbursement policies in developed countries.

Key Competitors and Market Share

Product	Company	Market Share (2022)	Key Differences
INVOKANA (canagliflozin)	Janssen (Johnson & Johnson)	20%	First in class, proven renal outcomes
Jardiance (empagliflozin)	Boehringer Ingelheim/Eli Lilly	22%	Strong cardiovascular data, global approval
Farxiga (dapagliflozin)	AstraZeneca	18%	Approved for heart failure and CKD
Others	Various	40%	Includes generics and smaller entities

---

Investment Outlook: Revenue and Financial Trajectory

Historical Performance

Year	Revenue (USD million)	Signal Events
2020	$823	Expanded label for heart failure
2021	$920	Clinical trial data on CKD
2022	$1,020	Increased global approvals

Revenue Projections (2023–2027)

Year	Estimated Revenue (USD million)	Key Assumptions
2023	$1,080	Continued uptake, emerging biosimilar threats
2024	$1,170	Additional label expansions, increased markets
2025	$1,270	Patent cliff approaching, biosimilar entries
2026	$1,370	Market adaptations, generic competition begins
2027	$1,480	Stabilization, new combination therapies

Projected CAGR: approximately 8% from 2022–2027.

Patent and Regulatory Outlook

• Patent expiries: Expected between 2025–2027 depending on jurisdiction.
• Biosimilar threat: Rising, can erode margins if not countered by differentiation.
• Regulatory approvals: Active expanding in Asia-Pacific, Latin America.

---

Commercial and Strategic Considerations

Opportunities

• Combination therapies: Co-administration with GLP-1 receptor agonists.
• Label Expansion: Broader indications for heart failure, CKD.
• Digital health initiatives: Remote monitoring aiding adherence.
• Emerging markets: Growth potential due to rising T2DM prevalence.

Risks

• Patent expiration: Potential revenue decline from biosimilar competition.
• Clinical setbacks: Significant adverse events could impair market perception.
• Regulatory delays: Could hinder expansion timelines.
• Pricing pressures: Increasing global cost containment measures.

Competitive Advantages

Factor	INVOKANA	Competitors
First-to-market	Yes	No
Clinical Evidence	Extensive CVOT (CANVAS, CREDENCE)	Competitive, but varied
Broadened Label	Yes (heart failure, CKD)	Yes, but varies per drug
Patent Position	Expiring soon	Varies

---

Deep Dive: Financial and Market Comparison

Revenue Breakdown by Geography (2022)

Region	Revenue (USD million)	Share of Total Revenue
North America	$410	40%
Europe	$280	27%
Asia-Pacific	$150	15%
Rest of World	$180	18%

Comparative Market Shares (2022)

Product	Market Share (%)	Key Differentiators
INVOKANA	20%	First-in-class, renal benefits
Jardiance	22%	CV and HF benefits, approvals in HF
Farxiga	18%	CKD, HF indications

Key Financial Metrics

Metric	2022 Value	2023 Projection
Gross Margin	~75%	Stable or slight increase
R&D Investment	Approx. 12% of revenue	Ongoing clinical development
Operating Margin	~25%	Slightly declining pre-patent expiry
Net Profit Margin	~20%	Expected to decrease post-patent

---

Strategic Recommendations for Investors

Focus Area	Actionable Insights
Patent Management	Prepare for potential decline post-2025, explore licensing/partnerships
Portfolio Diversification	Invest in combination therapies, new indications, and emerging markets
Competitive Profiling	Monitor biosimilar developments, differentiate through clinical data
Market Expansion	Prioritize markets with rising T2DM burden and favorable reimbursement
Digital and Data Strategies	Leverage digital health initiatives to improve adherence and outcomes

---

Conclusion

INVOKANA remains a high-potential asset within the expanding SGLT2 inhibitor market. Its growth trajectory is fueled by broadening indications and increasing global adoption, despite impending patent expiries and biosimilar threats. Strategic emphasis on indication expansion, pipeline strengthening, and market diversification will be critical to sustaining its financial trajectory.

---

Key Takeaways

• Market Growth: SGLT2 inhibitors are forecasted to grow at a CAGR of over 15%, with INVOKANA maintaining a significant share.
• Revenue Forecast: Estimated CAGR of 8% through 2027, with potential decline after patent expiry.
• Competitive Position: First-mover advantage and broad indications provide resilience; however, biosimilar competition is imminent.
• Strategic Focus: Diversify through label expansion, combination therapies, and global market penetration.
• Risks: Patent expiry, biosimilars, regulatory hurdles, and pricing pressures.

---

Frequently Asked Questions

1. When will INVOKANA’s patents expire, and how will this affect revenues?

Patent protection is expected to expire between 2025 and 2027, varying by country. Revenue may decline due to biosimilar entry, necessitating strategic diversification and innovation.

2. What are the key clinical benefits of INVOKANA supporting its market position?

INVOKANA has demonstrated significant reductions in cardiovascular events and renal disease progression in trials such as CANVAS and CREDENCE, underpinning its expanded label indications.

3. How does INVOKANA compare with competitors like Jardiance and Farxiga?

While INVOKANA was the first SGLT2 inhibitor approved, Jardiance and Farxiga have stronger cardiovascular (Jardiance) and CKD (Farxiga) data, potentially influencing market share dynamics.

4. What opportunities exist beyond T2DM for INVOKANA?

Label expansion into heart failure and CKD offers growth opportunities. Combination therapies with GLP-1 agonists are also promising avenues.

5. How are regulatory policies influencing INVOKANA’s market?

Increasing approvals in emerging markets and expanded indications in developed countries support market growth. However, cost containment policies may impose pricing pressures.

---

References

[1] GlobalData. (2022). Diabetes Therapeutics Market Report.
[2] IQVIA. (2022). Pharmaceutical Market Analysis.
[3] IDF Diabetes Atlas. (2021). Global prevalence estimates.